191 related articles for article (PubMed ID: 19905889)
1. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes.
Rodriguez L; Reyes E; Fagalde P; Oltra MS; Saba J; Aylwin CG; Prieto C; Ramos A; Galvao M; Gersin KS; Sorli C
Diabetes Technol Ther; 2009 Nov; 11(11):725-32. PubMed ID: 19905889
[TBL] [Abstract][Full Text] [Related]
2. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates.
Gersin KS; Rothstein RI; Rosenthal RJ; Stefanidis D; Deal SE; Kuwada TS; Laycock W; Adrales G; Vassiliou M; Szomstein S; Heller S; Joyce AM; Heiss F; Nepomnayshy D
Gastrointest Endosc; 2010 May; 71(6):976-82. PubMed ID: 20304396
[TBL] [Abstract][Full Text] [Related]
3. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial.
Koehestanie P; de Jonge C; Berends FJ; Janssen IM; Bouvy ND; Greve JW
Ann Surg; 2014 Dec; 260(6):984-92. PubMed ID: 25072436
[TBL] [Abstract][Full Text] [Related]
4. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner.
de Moura EG; Martins BC; Lopes GS; Orso IR; de Oliveira SL; Galvão Neto MP; Santo MA; Sakai P; Ramos AC; Garrido Júnior AB; Mancini MC; Halpern A; Cecconello I
Diabetes Technol Ther; 2012 Feb; 14(2):183-9. PubMed ID: 21932999
[TBL] [Abstract][Full Text] [Related]
5. Safety experience with the duodenal-jejunal bypass liner: an endoscopic treatment for diabetes and obesity.
Betzel B; Koehestanie P; Aarts EO; Dogan K; Homan J; Janssen IM; Wahab PJ; Groenen MJ; Berends FJ
Gastrointest Endosc; 2015 Nov; 82(5):845-52. PubMed ID: 25952090
[TBL] [Abstract][Full Text] [Related]
6. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner.
Escalona A; Pimentel F; Sharp A; Becerra P; Slako M; Turiel D; Muñoz R; Bambs C; Guzmán S; Ibáñez L; Gersin K
Ann Surg; 2012 Jun; 255(6):1080-5. PubMed ID: 22534421
[TBL] [Abstract][Full Text] [Related]
7. Endocrine effects of duodenal-jejunal exclusion in obese patients with type 2 diabetes mellitus.
Kaválková P; Mráz M; Trachta P; Kloučková J; Cinkajzlová A; Lacinová Z; Haluzíková D; Beneš M; Vlasáková Z; Burda V; Novák D; Petr T; Vítek L; Pelikánová T; Haluzík M
J Endocrinol; 2016 Oct; 231(1):11-22. PubMed ID: 27474690
[TBL] [Abstract][Full Text] [Related]
8. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes.
de Jonge C; Rensen SS; Verdam FJ; Vincent RP; Bloom SR; Buurman WA; le Roux CW; Schaper NC; Bouvy ND; Greve JW
Obes Surg; 2013 Sep; 23(9):1354-60. PubMed ID: 23526068
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes.
Cohen RV; Neto MG; Correa JL; Sakai P; Martins B; Schiavon CA; Petry T; Salles JE; Mamedio C; Sorli C
J Clin Endocrinol Metab; 2013 Feb; 98(2):E279-82. PubMed ID: 23337729
[TBL] [Abstract][Full Text] [Related]
10. Trends in BMI, Glycemic Control and Obesity-Associated Comorbidities After Explantation of the Duodenal-Jejunal Bypass Liner (DJBL).
Riedel N; Laubner K; Lautenbach A; Schön G; Schlensak M; Stengel R; Eberl T; Dederichs F; Aberle J; Seufert J
Obes Surg; 2018 Aug; 28(8):2187-2196. PubMed ID: 29504053
[TBL] [Abstract][Full Text] [Related]
11. The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort Study.
van Rijn S; Betzel B; de Jonge C; van Dijk DPJ; Janssen IM; Berends FJ; Bouvy ND; Greve JWM
Obes Surg; 2018 May; 28(5):1255-1262. PubMed ID: 29110244
[TBL] [Abstract][Full Text] [Related]
12. Is reimplantation of the duodenal-jejunal bypass liner feasible?
Koehestanie P; Betzel B; Aarts EO; Janssen IM; Wahab P; Berends FJ
Surg Obes Relat Dis; 2015; 11(5):1099-104. PubMed ID: 25979208
[TBL] [Abstract][Full Text] [Related]
13. Clinical follow-up on weight loss, glycemic control, and safety aspects of 24 months of duodenal-jejunal bypass liner implantation.
Betzel B; Cooiman MI; Aarts EO; Janssen IMC; Wahab PJ; Groenen MJM; Drenth JPH; Berends FJ
Surg Endosc; 2020 Jan; 34(1):209-215. PubMed ID: 30877567
[TBL] [Abstract][Full Text] [Related]
14. Effect of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Patients With Type 2 Diabetes With Obesity: A Meta-analysis With Secondary Analysis on Weight Loss and Hormonal Changes.
Jirapinyo P; Haas AV; Thompson CC
Diabetes Care; 2018 May; 41(5):1106-1115. PubMed ID: 29678867
[TBL] [Abstract][Full Text] [Related]
15. Acute pancreatitis as an adverse event in patients with the duodenal-jejunal bypass liner.
Betzel B; Homan J; Aarts E; Janssen I; Spanier M; Wahab P; Groenen M; Berends F
Endoscopy; 2015 Nov; 47(11):1050-3. PubMed ID: 26021308
[TBL] [Abstract][Full Text] [Related]
16. Changes in glycemic control and body weight after explantation of the duodenal-jejunal bypass liner.
Betzel B; Koehestanie P; Homan J; Aarts EO; Janssen IM; de Boer H; Wahab PJ; Groenen MJ; Berends FJ
Gastrointest Endosc; 2017 Feb; 85(2):409-415. PubMed ID: 27451295
[TBL] [Abstract][Full Text] [Related]
17. Impact of duodenal-jejunal bypass liner (DJBL) on NAFLD in patients with obesity and type 2 diabetes mellitus.
Roehlen N; Laubner K; Nicolaus L; Schwacha H; Bettinger D; Krebs A; Thimme R; Seufert J
Nutrition; 2022; 103-104():111806. PubMed ID: 36115281
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of the endoscopic duodenal-jejunal bypass liner prototype in severe or morbidly obese subjects implanted for up to 3 years.
Quezada N; Muñoz R; Morelli C; Turiel D; Hernández J; Pimentel F; Escalona A
Surg Endosc; 2018 Jan; 32(1):260-267. PubMed ID: 28664427
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of proximal small bowel exclusion by duodenal-jejunal bypass liner on weight reduction and glycemic control in diabetic patients.
Deutsch L; Ben Haim L; Sofer Y; Gluck N; Santo E; Fishman S
Surg Obes Relat Dis; 2018 Oct; 14(10):1561-1569. PubMed ID: 30449512
[TBL] [Abstract][Full Text] [Related]
20. Baseline glycated hemoglobin levels are associated with duodenal-jejunal bypass liner-induced weight loss in obese patients.
Muñoz R; Dominguez A; Muñoz F; Muñoz C; Slako M; Turiel D; Pimentel F; Sharp A; Escalona A
Surg Endosc; 2014 Apr; 28(4):1056-62. PubMed ID: 24196558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
